SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2002 / Cilt: 13 - Sayı: 4

Koledok taşı olan bir hastada artmış karbonhidrat antijen 19-9 düzeyleri

Elevated carbohydrate antigen 19-9 levels in a patient with choledocholithiasis

Ahmet K. GÜRBÜZ
A. Melih ÖZEL
Pages
213–215
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a 50-year-old woman with a common bile duct stone and cholangitis, whose CA 19-9 level of 1.500 U/ml returned to normal after definitive treatment of choledocholithiasis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Carbohydrate antigen 19-9 (CA19-9) has been used as a tumor marker in the diagnosis and differentiation of pancreatic cancers.
📊
Key Findings & Data:However, significantly high levels of CA 19-9 in the absence of pancreatic malignancy have also been reported.
💡
Conclusion & Impact:We present a 50-year-old woman with a common bile duct stone and cholangitis, whose CA 19-9 level of 1.500 U/ml returned to normal after definitive treatment of choledocholithiasis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Birleşik safra kanalı taşları · Tedavi sonucu · CA-19-9 antijen

Abstract

Carbohydrate antigen 19-9 (CA19-9) has been used as a tumor marker in the diagnosis and differentiation of pancreatic cancers. However, significantly high levels of CA 19-9 in the absence of pancreatic malignancy have also been reported. We present a 50-year-old woman with a common bile duct stone and cholangitis, whose CA 19-9 level of 1.500 U/ml returned to normal after definitive treatment of choledocholithiasis.

Özet

Karbohidrat antijen 19-9 (CA19-9) pankreas kanserlerinin ayırımı ve tanısında kullanılan bir tümör belirtecidir. Pankreas malinitesi olmayıp belirgin CA19-9 yüksekliği ile seyreden olgular bildirilmektedir. Bu yazıda tedavi öncesi Ca19-9 serum düzeyi 1500 U/l olup tedavi sonrasında tamamen normal düzeye düşen koledok taşlı 50 yaşında bir kadın olgu sunulmaktadır.

🔖

Cite This Article

GÜRBÜZ, A. K., ÖZEL, A. M. (2002). Koledok taşı olan bir hastada artmış karbonhidrat antijen 19-9 düzeyleri. Turkish Journal of Gastroenterology, Cilt: 13 - Sayı: 4, 213–215. https://ajindex.com/articles/411220

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-5
  2. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71
  3. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-6
  4. Steinberg W. The clinical utility of CA 19-9 tumor associated antigen. Am J Gastroenterol 1990; 85; 350-5
  5. Heptner G, Domschke S, Schneider MU, et al: Importance of the tumor-associated antigen CA 19-9 in the differential diagnosis of pancreatic diseases. Dtsch Med Wochenschr 1985; 110: 624-8
  6. Akdogan M, Sasmaz N, Kayhan B, et al. Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 2001; 87: 337-9
  7. Peterli R, Meyer-Wyss B, Herzog U, et al:CA19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 1999; 129: 77-9
  8. Tolliver BA, O'Brien BL. Elevated tumor-associated antigen CA 19-9 in a patient with an enlarged pancreas: does it always imply malignancy? South Med J 1997; 90: 89-90
  9. Suzuki K, Muraishi, Tokue A. The correlation of serum carbohydrate antigen19-9 with benign hydronephrosis. J Urology 2002; 167:16-20
  10. Murohisa T, Sugaya H, Tetsuka I, et al. A case of common bile duct stone with cholangitis presenting an extraordinarily high serum CA19-9 value. Intern Med 1992; 31: 516-20
  11. Gupta MK, Arciaga R, Bocci L, et al. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985; 56: 277-83
  12. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94: 1941-6
  13. Ohshio G, Manabe T, Watanabe Y, et al. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice. Am J Gastroenterol 1990; 85: 1370-6
  14. Buccheri GF, Ferrigno D, Sartoris AM, et al. Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoe